Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

被引：80

作者：

Boucau, Julie ^{[1
]}

Uddin, Rockib ^{[2
]}

Marino, Caitlin ^{[1
]}

Regan, James ^{[3
]}

Flynn, James P. ^{[3
]}

Choudhary, Manish C. ^{[3
,4
]}

Chen, Geoffrey ^{[2
]}

Stuckwisch, Ashley M. ^{[2
]}

Mathews, Josh ^{[2
]}

Liew, May Y. ^{[2
]}

Singh, Arshdeep ^{[2
]}

Reynolds, Zahra ^{[2
]}

Iyer, Surabhi L. ^{[2
]}

Chamberlin, Grace C. ^{[2
]}

Vyas, Tammy D. ^{[2
]}

Vyas, Jatin M. ^{[2
,4
]}

Turbett, Sarah E. ^{[2
]}

Li, Jonathan Z. ^{[3
,4
]}

Lemieux, Jacob E. ^{[2
,4
,5
]}

Barczak, Amy K. ^{[1
,2
,4
]}

Siedner, Mark J. ^{[2
,4
]}

机构：

[1] Massachusetts Inst Technol MIT & Harvard, Massachusetts Gen Hosp MGH, Ragon Inst, Cambridge, MA USA

[2] Massachusetts Gen Hosp, Boston, MA 02215 USA

[3] Brigham & Womens Hosp, Boston, MA 02215 USA

[4] Harvard Med Sch, Boston, MA 02215 USA

[5] Broad Inst, Cambridge, MA 02138 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 03期

关键词：

COVID-19; therapeutics; anti-virals; nirmatrelvir-ritonavir; virology;

D O I：

10.1093/cid/ciac512

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log(10) copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

引用

页码：E526 / E529

页数：4

共 50 条

[31] Underutilization of nirmatrelvir/ritonavir in eligible COVID-19 patients [J].

de Arpe, Celia Fortea ;

Homen, Reynaldo ;

Valls-Carbo, Adrian ;

Barrado, Julia ;

Olmos-Mata, Carolina ;

Perez-Somarriba, Juncal ;

Munoz-Gomez, Ana ;

Nunez-Orantos, Maria Jose ;

Cabello-Clotet, Noemi ;

Estrada, Vicente .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2025,

[32] Nirmatrelvir-Ritonavir for Acute COVID-19 in Patients With Cardiovascular Disease and Postacute Sequelae of SARS-CoV-2 Infection [J].

Patel, Rushin ;

Dani, Sourbha S. ;

Khadke, Sumanth ;

Kumar, Ashish ;

Ahmad, Javaria ;

Saji, Anu Mariam ;

Shah, Jui ;

Mehta, Neev ;

Wener, Kenneth ;

Mcquillen, Daniel P. ;

Abraham, George ;

Faust, Jeremy ;

Maley, Jason ;

Patel, Smita ;

Mullington, Janet ;

Wachter, Robert M. ;

Mosenthal, Anne ;

Sax, Paul E. ;

Ganatra, Sarju .

JACC-ADVANCES, 2024, 3 (06)

[33] New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19 [J].

Atmar, Robert L. ;

Finch, Natalie .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (08)

[34] Nirmatrelvir/ritonavir treatment and risk for postacute sequelae of COVID-19 in older Singaporeans [J].

Wee, Liang En ;

Lim, Jue Tao ;

Tay, An Ting ;

Chiew, Calvin J. ;

Young, Barnaby Edward ;

Wong, Betty ;

Lim, Ruth ;

Li Lee, Ching ;

Tan, Joyce ;

Vasoo, Shawn ;

Lye, David Chien ;

Tan, Kelvin Bryan .

CLINICAL MICROBIOLOGY AND INFECTION, 2025, 31 (01) :93-100

[35] Effectiveness and safety of remdesivir and nirmatrelvir-ritonavir in mild to moderate COVID-19 in spanish hospital emergency departments [J].

Rodriguez-Leal, Cristobal M. ;

del Castillo, Juan Gonzalez ;

Ruiz Grinspan, Martin Sebastian ;

Garcia, Rosario Susi ;

Perez, Teresa Perez .

MEDICINA CLINICA, 2025, 165 (02)

[36] Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study [J].

Deng, Guangtong ;

Li, Daishi ;

Sun, Yuming ;

Jin, Liping ;

Zhou, Qian ;

Xiao, Chenggen ;

Wu, Qingrong ;

Sun, Huiyan ;

Dian, Yating ;

Zeng, Furong ;

Pan, Pinhua ;

Shen, Minxue .

JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (04)

[37] Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19 [J].

Lu, Jiayue ;

Cai, Hong ;

Hao, Yujun ;

Lin, Zhang ;

Liu, Shang ;

Zhan, Yaping ;

Ding, Li ;

Huang, Meilan ;

Li, Zhenyuan ;

Xu, Lan ;

Yan, Xiujuan ;

Yang, Li ;

Zhang, He ;

Zhang, Wei ;

Zhao, Li ;

Zhao, Junli ;

Wang, Ting ;

Gu, Leyi .

FRONTIERS IN PHARMACOLOGY, 2023, 14

[38] Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19 [J].

Jang, Young Rock ;

Oh, Yoonju ;

Kim, Jin Yong .

JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (06)

[39] Evaluating the safety and efficacy of nirmatrelvir-ritonavir therapy in pregnant women with COVID-19: a systematic review and meta-analysis [J].

Hassan, Omar ;

Elbhairy, Aya Abdulkarim ;

Siam, Aya Magdy ;

Abdelwahab, Tasneem ;

Hamad, Albraa Ashraf ;

Mahmoud, Omar Ehab ;

Nabeh, Omnia Azmy .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 81 (04) :495-506

[40] Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir [J].

Akinosoglou, Karolina ;

Schinas, Georgios ;

Gogos, Charalambos .

VIRUSES-BASEL, 2022, 14 (11)

← 1 2 3 4 5 →